Abstract. Hypoxia-inducible factor-1α (HIF-1α) and differentiated embryo-chondrocyte expressed gene 1 (DEC1) are two key factors that protect hepatocellular carcinoma (HCC) cells from a hypoxic microenvironment. However, little is known concerning the effects of hypoxia on the expression of HIF-1α and DEC1 in HCC. In the present study, RT-PCR and western blotting were conducted to assay the mRNA and protein levels of HIF-1α and DEC1 under normoxia and hypoxia induced by exposure to CoCl 2 for different time periods (0, 2, 4, 6, 24 and 48 h). In addition, the HIF-1α protein inhibitor, YC-1, was used to analyze the interaction between DEC1 and HIF-1α expression and the related mechanism. Results showed that expression of DEC1 in HCC was significantly upregulated at both the mRNA and protein levels, when compared with that in normal liver cells (P<0.05). Hypoxia induced the upregulation of HIF-1α in a time-dependent manner, which was also observed at the DEC1 mRNA and protein levels (P<0.05). However, hypoxia did not affect the transcription of HIF-1α (P>0.05). A positive correlation was found between HIF-1α and DEC1 expression in both BEL-7402 (r=0.885, P<0.05) and P<0.05). Furthermore, inhibition of HIF-1α by YC-1 led to a significant decrease in DEC1 induced by hypoxia (P<0.05). We suggest that hypoxia induced the overexpression of DEC1, the mechanism of which may be related to the upregulation of HIF-1α in HCC. The efficacy of inhibiting HIF-1α and DEC1 expression as a possible treatment for HCC should be assessed in clinical trials.
Introduction
Hypoxia is a universal characteristic of the microenvironment in many solid tumors, including hepatocellular carcinoma (HCC) (1) . A hypoxic microenvironment affects the tumor cell phenotype, activates angiogenesis-related growth factors, upregulates a variety of proteins and enzymes on which tumor cell energy metabolism depends (2, 3) . Hypoxia further exacerbates the genetic instability of tumor cells, activates various tumor survival factors and promotes tumor metastasis. Therefore, a hypoxic microenvironment is closely related to cancer development, prognosis and metastasis (4) . Research on hypoxia focusing on the future treatment of cancer has received increased attention.
By initiating a series of adaptive responses, tumor cells adapt and survive in the hypoxic microenvironment. Hypoxiainducible factor-1α (HIF-1α) is considered to be the central initiating molecule of tumor hypoxic adaptive responses. HIF-1α locates on chromosome 14 (14q21-24) and encodes 826 amino acids. HIF-1α regulates a series of events concerning hypoxic-related gene transcription and expression by binding with HIF-1β (5) . More than 100 types of genes have been determined as targets of HIF-1α under hypoxia. These genes are mainly categorized into 4 main types: angiogenesis-related factors, glucose transporters and glycolytic enzymes, tumor invasion and metastasis-related factors and cell proliferation and apoptosis-related factors (6, 7) . Therefore, HIF-1α plays an important role in tumor cell proliferation, apoptosis, invasion and metastasis under hypoxia.
Differentiated embryo-chondrocyte expressed gene 1 (DEC1), also known as SHARP-2 or Stra13, locates on human chromosome 3p25.3-26 and is a basic helix-loop-helix (bHLH) transcriptional factor (8) . DEC1 protein is synthesized in the cytoplasm and forms homodimers or heterodimers. It translocates into the nucleus and regulates target gene transcription and expression by binding with E-box elements (9) . DEC1 was found to be overexpressed in many tumor types such as leukemia, colon and lung cancer and glioma (10, 11) . Recently, research has confirmed DEC1 as a hypoxic-regulated gene with important links to tumor development under hypoxia (12) .
A correlation between HIF-1α and DEC1 expression has been found in some tumor types, and we previously demonstrated that their overexpression may be direct markers for tumors in hypoxia (13) . DEC1 expression was also confirmed to be directly related to the expression of HIF-1α in nonsmall cell lung carcinomas (12) . In primary human breast carcinomas, DEC1 has been defined as an HIF-1α regulated gene (14) . However, no similar reports exist concerning the relationship between HIF-1α and DEC1 expression in HCC, particularly in regards to whether DEC1 is a downstream target gene under hypoxia in HCC. In order to ascertain whether a correlation exists between HIF-1α and DEC1 under hypoxia, we conducted the present study using the human normal liver cell line, QSG-7701 and hepatoma cell lines, BEL-7402 and SMMC-7721. Chemical hypoxia agent cobalt chloride (CoCl 2 ) was applied to simulate the hypoxic microenvironment in vivo. HIF-1α and DEC1 expression under hypoxic conditions was assessed. HIF-1α inhibitor, YC-1, was applied to cultured cells to explore the interaction and possible mechanism between DEC1 and HIF-1α expression. Our results showed that hypoxia induced the overexpression of DEC1, which was restricted in relation to the inhibition of HIF-1α expression by YC-1. We speculate that hypoxia-induced overexpression of DEC1 is regulated by HIF-1α in HCC. These findings may provide theoretical support for their future clinical trials in regards to the treatment of HCC.
Materials and methods

Materials.
The human normal liver cell line (QSG-7701) and hepatoma cell lines (BEL-7402 and SMMC-7721) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The media and serum were purchased from Gibco (Carlsbad, CA, USA). TRIzol and RT-PCR kits were products of Takara. Anti-DEC1 and anti-HIF-1α antibodies were purchased from Novus Biologicals (Littleton, CO, USA). GAPDH and the secondary antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cell culture and the experimental groups. All cells were cultured in RPMI-1640 medium (Gibco) containing 10% fetal bovine serum (FBS; Gibco), 100 U/ml penicillin and 100 mg/ ml streptomycin at 37˚C in a 5% CO 2 atmosphere. Cells were lysed with 0.25% Trypsin-EDTA (Gibco) for further passage, and cells at a logarithmic growth phase were used for subsequent study.
Generally, cells were cultured in a normoxic condition without CoCl 2 exposure (0 h group) and in a hypoxic condition (CoCl 2 200 µM for 2, 4, 6, 24 and 48 h). For further mechanistic analysis, YC-1 (50 µM) was applied, and cells were cultured as follows: normoxic group, cells were cultured in a normoxic condition at 37˚C in a 5% CO 2 atmosphere; hypoxia group, cells were cultured in a normoxic condition but exposed to CoCl 2 (200 µM) for 4 h; hypoxia + YC-1 (50 µM) culture group, cells were cultured in a normoxic condition but were exposure to both CoCl 2 (200 µM) and YC-1 (50 µM) for 4 h.
RNA isolation and reverse transcription-PCR.
Total RNA was extracted using TRIzol (Invitrogen) in accordance with the manufacturer's instructions. M-MuLV reverse transcription (Takara) was used for mRNA measurements. In brief, RT was performed using the ExScript RT reagent kit (Takara Bio, Otsu, Shiga, Japan) in a final volume of 20 µl containing 1 µg total RNA, 4 µl 5X ExScript buffer, 1 µl deoxynucleotide triphosphate (dNTP, 10 µM) mixture, 1 µl oligo(dT) primer, 0.5 µl ExScript RTase, 0.5 µl RNase inhibitor and RNase-free water. PCR was conducted according to the instructions of Takara Taq™ under the following conditions: pre-DNA denaturation at 95˚C for 3 min; DNA denaturation at 95˚C for 45 sec; annealing for 40 sec at 56˚C; elongation was carried out at 72˚C for 50 sec; the total cycle number was 30. All experiments were performed in triplicate. The relative OD ratio was calculated using the NIH ImageJ software with β-actin as an internal control. The products of HIF-1α, DEC1 and β-actin were 338, 395 and 152 bp, respectively. The primers were as follows: HIF-1α-F, 5'-TCCATGTGACCA TGAGGAAA-3' and HIF-1α-R, 5'-TATCCAGGCTGTGTC GACTG-3'; DEC1-F, 5'-GTACCCTGCCCACATGTACC-3' and DEC1-R, 5'-GCTTGGCCAGATACTGAAGC-3'; β-actin-F, 5'-AGTTGCGTTACACCCTTTC-3' and β-actin-R, 5'-CCTTCACCGTTCCAGTTT-3'.
Protein extraction and western blot analysis. Total protein was extracted using radioimmunoprecipitation assay buffer (RIPA) and protein lysis buffer according to standard protocols. The Bradford method was used to determine the protein concentration of the supernatant. Samples (40 µg of total protein each) were subjected to western blot analysis with the primary antibodies (HIF-1α 1:1,000; DEC1 1:500; GAPDH 1:3,000). The HIF-1α, DEC1 and GAPDH bands were visualized at apparent molecular weights of 120, 45 and 36 kDa, respectively. The relative OD ratio was calculated with NIH ImageJ software by comparison with GAPDH from three experiments.
Statistical analysis. Data are presented as means ± standard error of the mean (SEM). Statistical calculations were performed using SPSS 16.0 software package. One-way analysis of variance (ANOVA) was applied for analysis. P-values of <0.05 were considered to indicate statistically significant results.
Results
DEC1 is expressed in the normal liver and hepatoma cell lines.
As shown in Fig. 1, DEC1 was detected in the normal liver QSG-7701 cells and in the hepatoma BEL-7402 and SMMC-7721 cells at both the mRNA and protein levels. Compared with the control QSG-7701 cells considered as 100%, the relative photodensities of RT-PCR detection in the BEL-7402 and SMMC-7721 cells were 409.87±67.58 and 491.8±57.95% (Fig. 1A and B) and in the western blot analysis, 284.37±41.32 and 402.01±21.87%, respectively (Fig. 1C and  D) . Statistical analysis showed that DEC1 was expressed at a significantly higher level in the BEL-7402 and SMMC-7721 cells than that in the QSG-7701 cells; DEC1 exhibited nearly 4-fold increased expression in hepatoma as determined by ImageJ software analysis (P<0.05). The results suggest that DEC1 is closely correlated with hepatoma and may play an important role in hepatoma progression.
A hypoxic microenvironment induces the transcription of DEC1. Both SMMC-7721 and BEL-7402 cells were exposed to CoCl 2 (200 µM) for 2, 4, 6, 24 and 48 h to induce a hypoxic condition. RT-PCR assay showed that DEC1 mRNA transcription was enhanced, particularly in the cell groups exposed to CoCl 2 (200 µM) for 4 h when compared with that in a normoxic condition (0 h group). Considering the control group (0 h group) as 100%, the relative photodensities of SMMC-7721 cells induced by CoCl 2 
HIF-1α and DEC1 expression is upregulated under hypoxia.
Western blot analysis confirmed the upregulation of both DEC1 and HIF-1α under hypoxia induced by CoCl 2 (200 µM) for 2, 4, 6, 24 and 48 h in both SMMC-7721 and BEL-7402 cells. Significance was achieved when compared with that in a normoxic condition (0 h group) (P<0.05). Peaks in expression were noted for DEC1 and HIF-1α in both cell lines following exposure to CoCl 2 (200 µM) for 4 h. Even following long-term hypoxia (exposure for 24 and 48 h), HIF-1α and DEC1 both Pearson correlation analysis between DEC1 and HIF-1α expression under hypoxia. A highly positive correlation was found between HIF-1α and DEC1 protein expression according to Pearson rank correlation analysis in both BEL-7402 and SMMC-7721 cells. Rank related coefficient (r) was respectively: r BEL-7402 =0.885, P<0.05 and r SMMC-7721 =0.826, P<0.05. This result suggests that DEC1 expression under hypoxia may be positively regulated by HIF-1α (Fig. 3) .
Inhibition of HIF-1α restricts the overexpression of DEC1
induced by hypoxia. To further explore the possible mechanism of hypoxia in modulating DEC1 expression, we hypothesized that DEC1 is a downstream target gene of HIF-1α. YC-1, a specific HIF-1α inhibitor, was applied to inhibit HIF-1α expression. RT-PCR and western blot analysis were both conducted in BEL-7402 and SMMC-7721 cells. Compared with cultures in normoxic conditions, YC-1 (50 µM) inhibited the expression of HIF-1α and markedly restricted the upregulation of DEC1 induced by hypoxia, suggesting that DEC1 expression is modulated by HIF-1α under hypoxia (Fig. 4) .
Discussion
The rapid proliferation of cancer cells often leads to hypoxia in tissues. Therefore, adaptation to hypoxia becomes a key step in the development of tumors, including HCC. HIF-1 is the most important transcriptional factor in hypoxia. Hundreds of downstream target genes, such as vascular endothelial growth factor (VEGF), erythropoietin (EPO), the oxygen-regulated proteins (ORPs) and inducible nitric oxide synthase (iNOS) are believed to be regulated by HIF-1 under hypoxia (6, 7) . They enhance the resistance of tumor cells to hypoxia and promote the growth of tumor cells and malignant transformation (15) . HIF-1 is comprised of α and β subunits. The β subunit is a structural subunit stably expressed in cells, and the α subunit is functional and its expression is regulated by the oxygen concentration of cells (5) . Under normoxia, the tumor-suppressor protein (pVHL) combined with the oxygendependent degradation domain (ODD) of HIF-1α leads to the degradation of HIF-1α by the ubiquitin-proteasome pathway (16) . Under hypoxia, the degradation pathway is inhibited, and HIF-1α protein expression is enhanced. In the present study, CoCl 2 was applied to simulate hypoxia in cells. Results showed that HIF-1α expression was virtually undetectable in normoxia, and was significantly increased under hypoxia in a time-dependent manner. In fact, upregulation of HIF-1α induced by hypoxia has been confirmed in many tumor types. However, no significant changes were noted at the HIF-1α mRNA level. This demonstrated that the regulation of HIF-1α under hypoxia occurred mainly at the post-transcriptional level. Similar findings were noted in breast cancer (17) .
The DEC1 gene is located on human chromosome 3p25.3-26 and is a basic helix-loop-helix (bHLH) transcriptional factor. It has been reported that DEC1 is overexpressed in many tumor types such as breast, colon, lung, stomach cancer and glioma (18) . DEC1 plays important roles in tumor cell proliferation, apoptosis and differentiation. Our previous study showed that DEC1 was overexpressed in HCC, and was closely related to HCC progression (19) . Recently, research has confirmed DEC1 as a hypoxic-regulated gene. Using differential expression analysis, Wykoff et al (20) demonstrated the hypoxia-induced expression of DEC1 in lung, pancreatic, bladder cancer, and renal cell carcinoma cell lines. In our previous study, we induced high expression of DEC1 in various cell lines of gastric cancer by application of a CoCl 2 hypoxia model (21) . In the present study, we investigated hypoxia-induced expression of DEC1 in HCC cell lines. Our results revealed that DEC1 expression was enhanced under hypoxia in a time-dependent manner in both BEL-7402 and SMMC-7721 cells, and maintained a high level even under hypoxia for 24 and 48 h, indicating that DEC1 plays an important role in adaptation to a hypoxic microenvironment in HCC.
A correlation between DEC1 and HIF-1α expression has been reported in many tumor tissues. Chakrabarti et al (22) confirmed that DEC1 and HIF-1α were significantly correlated as detected by immunohistochemistry in breast cancer. In order to further clarify the relationship between DEC1 and HIF-1α in HCC, the HIF-1α protein inhibitor YC-1 was applied. After application of YC-1, HIF-1α protein expression was significantly decreased but no obvious change at the mRNA level was noted. Along with the reduced expression of HIF-1α following exposure of HCC cells to YC-1, DEC1 mRNA and protein expression was significantly downregulated, suggesting that DEC1 expression is regulated by HIF-1 under hypoxia. The possible mechanism appears to be that HIF-1α protein binds with the hypoxia-response element (HRE) located in the promoter of DEC1 and further activates the transcription and regulation of DEC1 (23) .
In summary, we investigated the role of hypoxia on HIF-1α and DEC1 expression in HCC and confirmed a positive correlation. We found that inhibition of HIF-1α by YC-1 restricted the overexpression of DEC1 induced by hypoxia. HIF-1α and DEC1 may be potential candidates for the future gene-targeted therapy of HCC.
